

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 July 2023 (13.07.2023)



(10) International Publication Number
WO 2023/131690 A1

(51) International Patent Classification:

C07D 277/56 (2006.01) A61P 35/00 (2006.01)
C07D 413/12 (2006.01) A61K 31/4725 (2006.01)
C07D 413/14 (2006.01) A61K 31/427 (2006.01)
C07D 417/12 (2006.01) A61K 31/4245 (2006.01)
C07D 417/14 (2006.01) A61K 31/426 (2006.01)

(21) International Application Number:

PCT/EP2023/050255

(22) International Filing Date:

09 January 2023 (09.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

22150667.8 10 January 2022 (10.01.2022) EP

(71) Applicant: **MERCK PATENT GMBH** [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).

(72) Inventors: **BUCHSTALLER, Hans-Peter**; c/o Merck KGaA, Frankfurter Strasse 250, 64293 DARMSTADT (DE). **KUHN, Daniel**; c/o Merck KGaA, Frankfurter Strasse 250, 64293 DARMSTADT (DE). **COLLINS, Ian**; c/o The Institute of Cancer Research: Royal Cancer Center, 123 Old Brompton Road, LONDON SW7 3RP (GB). **MATTHEWS, Thomas**; c/o The Institute of Cancer Research: Royal Cancer Center, 123 Old Brompton Road, LONDON SW7 3RP (GB). **LANZ, Jan**; c/o The Institute of Cancer Research: Royal Cancer Center, 123 Old Brompton Road, LONDON SW7 3RP (GB). **CALDWELL, John**; c/o The Institute of Cancer Research: Royal Cancer Center, 123 Old Brompton Road, LONDON SW7 3RP (GB). **COLOMBANO, Giampiero**; c/o The Institute of Cancer Research: Royal Cancer Center, 123 Old Brompton Road, LONDON SW7 3RP (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,


TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: SUBSTITUTED HETEROCYCLES AS HSET INHIBITORS



(57) Abstract: The invention relates to substituted heterocycles of the general formula (I), wherein W is thiazole, thiophene, pyrazole, imidazole or isoxazole, and the use of the compounds of the present invention for the treatment and/or prevention of hyperproliferative diseases and disorders in mammals, especially humans, and pharmaceutical compositions containing such compounds.



WO 2023/131690 A1